TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC) Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option SEONGNAM, South Korea, May 31, 2026 /PRNewswire/ -- TiumBio Co....
75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC) Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option SEONGNAM, South Korea, May 31, 2026 /PRNewswire/ -- TiumBio Co....
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.